A tour through the transcriptional landscape of platelets

Blood

Volumn 124, Issue 4, 2014, Pages 493-502

  Schubert, Sebastian ^a   Weyrich, Andrew S ^a,b   Rowley, Jesse W ^a,b  

^a Program in Molecular Medicine   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; MESSENGER RNA; POLYADENYLIC ACID; RNA; TRANSCRIPTION FACTOR;

GENE DELETION; GENE INSERTION; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; RNA STRUCTURE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; TOPOGRAPHY;

ANIMALS; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATION; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84904915119     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-512756     Document Type: Review

References (109)

1. Rowley JW, Oler AJ, Tolley ND, et al. Genomewide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118(14): e101-e111.
2. Rowley JW, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the message. Curr Opin Hematol. 2012;19(5):385-391.
3. Lood C, Amisten S, Gullstrand B, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood. 2010;116(11):1951-1957.
4. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113(19):2278-2284. (Pubitemid 43947973)
5. Goodall AH, Burns P, Salles I, et al; Bloodomics Consortium. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood. 2010;116(22): 4646-4656.
6. Simon LM, Edelstein LC, Nagalla S, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood. 2014;123(16):e37-e45.
7. Edelstein LC, Simon LM, Montoya RT, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. 2013;19(12):1609-1616.
8. Plé H, Maltais M, Corduan A, Rousseau G, Madore F, Provost P. Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost. 2012;108(4):605-615.
9. McManus DD, Beaulieu LM, Mick E, et al. Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2013;33(11):2666-2673.
10. Freedman JE, Larson MG, Tanriverdi K, et al. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation. 2010; 122(2):119-129.
11. Raghavachari N, Xu X, Harris A, et al. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation. 2007;115(12):1551-1562. (Pubitemid 46648640)
12. Sun L, Gorospe JR, Hoffman EP, Rao AK. Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost. 2007; 5(1):146-154. (Pubitemid 44921080)
13. Gnatenko DV, Zhu W, Xu X, et al. Class prediction models of thrombocytosis using genetic biomarkers. Blood. 2010;115(1):7-14.
14. Risitano A, Beaulieu LM, Vitseva O, Freedman JE. Platelets and platelet-like particles mediate intercellular RNA transfer. Blood. 2012;119(26): 6288-6295.
15. Clancy L, Freedman JE. New paradigms in thrombosis: novel mediators and biomarkers platelet RNA transfer. J Thromb Thrombolysis. 2014;37(1):12-16.
16. Laffont B, Corduan A, Plé H, et al. Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood. 2013;122(2):253-261.
17. Gidlöf O, van der Brug M, Ohman J, et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood. 2013;121(19):3908-3917, S1-S26.
18. Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray PF. MicroRNAs in platelet production and activation. J Thromb Haemost. 2013;11(suppl 1):340-350.
19. Dangwal S, Thum T. MicroRNAs in platelet physiology and pathology. Hamostaseologie. 2013;33(1):17-20.
20. Bray PF, McKenzie SE, Edelstein LC, et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics. 2013;14(1):1.
21. Londin ER, Hatzimichael E, Loher P, et al. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biol Direct. 2014;9(1):3.
22. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): highperformance genomics data visualization and exploration. Brief Bioinform. 2013;14(2): 178-192.
23. Kissopoulou A, Jonasson J, Lindahl TL, Osman A. Next generation sequencing analysis of human platelet PolyA+ mRNAs and rRNAdepleted total RNA. PLoS ONE. 2013;8(12): e81809.
24. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12(2):87-98.
25. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57-63.
26. Costa V, Angelini C, De Feis I, Ciccodicola A. Uncovering the complexity of transcriptomes with RNA-Seq. J. Biomed. Biotechnol. 2010; 2010:853916.
27. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5(7):621-628. (Pubitemid 351911867)
28. Plé H, Landry P, Benham A, Coarfa C, Gunaratne PH, Provost P. The repertoire and features of human platelet microRNAs. PLoS ONE. 2012;7(12):e50746.
29. Kuhn RM, Haussler D, Kent WJ. The UCSC genome browser and associated tools. Brief Bioinform. 2013;14(2):144-161.
30. Dillies MA, Rau A, Aubert J, et al; French StatOmique Consortium. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis. Brief Bioinform. 2013;14(6):671-683.
31. Garber M, Grabherr MG, Guttman M, Trapnell C. Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods. 2011;8(6):469-477.
32. Carmody SR, Wente SR. mRNA nuclear export at a glance. J Cell Sci. 2009;122(pt 12): 1933-1937.
33. Shatkin AJ, Manley JL. The ends of the affair: capping and polyadenylation. Nat Struct Biol. 2000;7(10):838-842.
34. Kong J, Lasko P. Translational control in cellular and developmental processes. Nat Rev Genet. 2012;13(6):383-394.
35. Norbury CJ. Cytoplasmic RNA: a case of the tail wagging the dog. Nat Rev Mol Cell Biol. 2013; 14(10):643-653.
36. Schoenberg DR, Maquat LE. Regulation of cytoplasmic mRNA decay. Nat Rev Genet. 2012; 13(4):246-259.
37. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA. 2003;100(1): 189-192. (Pubitemid 36078050)
38. Roth GJ, Hickey MJ, Chung DW, Hickstein DD. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem Biophys Res Commun. 1989;160(2): 705-710. (Pubitemid 19140590)
39. Houng AK, Maggini L, Clement CY, Reed GL. Identification and structure of activated-platelet protein-1, a protein with RNA-binding domain motifs that is expressed by activated platelets. Eur J Biochem. 1997;243(1-2):209-218. (Pubitemid 27060404)
40. Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang. 2010;99(2): 112-122.
41. Choi YH, Hagedorn CH. Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3′ poly(A) end phenotype. Proc Natl Acad Sci USA. 2003;100(12):7033-7038. (Pubitemid 36706388)
42. Marzluff WF, Wagner EJ, Duronio RJ. Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet. 2008;9(11):843-854.
43. Pickrell JK, Marioni JC, Pai AA, et al. Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature. 2010;464(7289):768-772.
44. Osei-Bimpong A. The effect of storage on the clinical utility of the immature platelet fraction. Hematology. 2009;14(2):118-121.
45. Nishiyama M, Hayashi S, Kabutomori O, et al. Effects of anticoagulants and storage temperature on immature platelet fraction % (IPF%) values in stored samples measured by the automated hematology analyzer, XE-5000-utility of CTAD-anticoagulation and room temperature storage [in Japanese]. Rinsho Byori. 2011;59(5):452-458.
46. Stiegler G, Fischer G, Ramanathan G, Bencur P, Weigel G, Mannhalter C. P-selectin mRNA is maintained in platelet concentrates stored at 4 degrees C. Transfusion. 2009;49(5):921-927.
47. Blache D, Becchi M, Davignon J. Occurrence and biological effects of cholesteryl sulfate on blood platelets. Biochim Biophys Acta. 1995; 1259(3):291-296. (Pubitemid 26014982)
48. Yanai I, Benjamin H, Shmoish M, et al. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics. 2005;21(5): 650-659. (Pubitemid 40424791)
49. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent premRNA splicing in anucleate platelets. Cell. 2005; 122(3):379-391. (Pubitemid 41127140)
50. Schwertz H, Tolley ND, Foulks JM, et al. Signaldependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med. 2006;203(11):2433-2440. (Pubitemid 44664613)
51. Münzer P, Tolios A, Pelzl L, et al. Thrombinsensitive expression of the store operated Ca(2+) channel Orai1 in platelets. Biochem Biophys Res Commun. 2013;436(1):25-30.
52. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005;41(16): 2449-2461. (Pubitemid 41540622)
53. Dittrich M, Birschmann I, Pfrang J, et al. Analysis of SAGE data in human platelets: features of the transcriptome in an anucleate cell. Thromb Haemost. 2006;95(4):643-651.
54. Jia J, Yao P, Arif A, Fox PL. Regulation and dysregulation of 3'UTR-mediated translational control. Curr Opin Genet Dev. 2013;23(1):29-34.
55. Matoulkova E, Michalova E, Vojtesek B, Hrstka R. The role of the 3′ untranslated region in posttranscriptional regulation of protein expression in mammalian cells. RNA Biol. 2012;9(5):563-576.
56. Rosenberg BR, Hamilton CE, Mwangi MM, Dewell S, Papavasiliou FN. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 39 UTRs. Nat Struct Mol Biol. 2011;18(2):230-236.
57. van der Velden AW, Thomas AA. The role of the 5′ untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol. 1999;31(1):87-106. (Pubitemid 29094792)
58. Barbosa C, Peixeiro I, Romão L. Gene expression regulation by upstream open reading frames and human disease. PLoS Genet. 2013; 9(8):e1003529.
59. Lai EC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002; 30(4):363-364.
60. Weyrich AS, Denis MM, Schwertz H, et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood. 2007;109(5):1975-1983. (Pubitemid 46348195)
61. Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Duménil D. Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood. 2010;115(14): 2784-2795.
62. Monteferrario D, Bolar NA, Marneth AE, et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med. 2014;370(3): 245-253.
63. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102-114.
64. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16(9):961-966.
65. Stratz C, Nührenberg TG, Binder H, et al. Micro-array profiling exhibits remarkable intraindividual stability of human platelet micro-RNA. Thromb Haemost. 2012;107(4):634-641.
66. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011; 117(19):5189-5197.
67. Edelstein LC, Bray PF. Small RNAs as potential platelet therapeutics. In: Gresele P, Born GVR, Patrono C, Page CP, eds. Antiplatelet Agents. Handbook of Experimental Pharmacology, Vol 210. Berlin: Springer; 2012:435-445.
68. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013;33(2):206-214.
69. Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L, Congdon CB. Common features of microRNA target prediction tools. Front Genet. 2014;5:23.
70. Smyth SS, Woulfe DS, Weitz JI, et al; 2008 Platelet Colloquium Participants. G-proteincoupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol. 2009;29(4):449-457.
71. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998;273(4):2030-2034. (Pubitemid 28069249)
72. Hechler B, Gachet C. P2 receptors and platelet function. Purinergic Signal. 2011;7(3):293-303.
73. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5(10):1199-1202. (Pubitemid 29474427)
74. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2004;2(11):e363.
75. Johnson AD, Yanek LR, Chen M-H, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42(7): 608-613.
76. Kauskot A, Di Michele M, Loyen S, Freson K, Verhamme P, Hoylaerts MF. A novel mechanism of sustained platelet aIIbb3 activation via PEAR1. Blood. 2012;119(17):4056-4065.
77. Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456(7221): 470-476. (Pubitemid 352759009)
78. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413-1415.
79. Passetti F, Ferreira CG, Costa FF. The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J. 2009;9(1):1-13.
80. Power KA, McRedmond JP, de Stefani A, Gallagher WM, Gaora PO. High-throughput proteomics detection of novel splice isoforms in human platelets. PLoS ONE. 2009;4(3):e5001.
81. Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934-2943.
82. Ellery PER, Maroney SA, Martinez ND, Wickens MP, Mast AE. Translation of human tissue factor pathway inhibitor-β mRNA is controlled by alternative splicing within the 5′ untranslated region. Arterioscler Thromb Vasc Biol. 2014; 34(1):187-195.
83. Maroney SA, Ellery PE, Wood JP, Ferrel JP, Martinez ND, Mast AE. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)a and TFPIb. J Thromb Haemost. 2013;11(5):911-918.
84. Fox JE. Shedding of adhesion receptors from the surface of activated platelets. Blood Coagul Fibrinolysis. 1994;5(2):291-304. (Pubitemid 24138066)
85. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells. 1990;16(1):73-80, discussion 80-83.
86. Johnston GI, Bliss GA, Newman PJ, McEver RP. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J Biol Chem. 1990;265(34):21381-21385. (Pubitemid 120014165)
87. Ishiwata N, Takio K, Katayama M, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem. 1994;269(38):23708-23715. (Pubitemid 24293578)
88. Semenov AV, Romanov YA, Loktionova SA, et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc.). 1999;64(11):1326-1335. (Pubitemid 129583383)
89. Djaffar I, Chen YP, Creminon C, et al. A new alternative transcript encodes a 60 kDa truncated form of integrin beta 3. Biochem. J. 1994;300(pt 1):69-74. (Pubitemid 24151018)
90. Markovic B, Wu Z, Chesterman CN, Chong BH. Quantitation of soluble and membrane-bound Fc gamma RIIA (CD32A) mRNA in platelets and megakaryoblastic cell line (Meg-01). Br J Haematol. 1995;91(1):37-42.
91. Censarek P, Steger G, Paolini C, et al. Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting. Thromb Haemost. 2007;98(6):1309-1315. (Pubitemid 350239103)
92. Sun L, Mao G, Kunapuli SP, Dhanasekaran DN, Rao AK. Alternative splice variants of phospholipase C-beta2 are expressed in platelets: effect on Galphaq-dependent activation and localization. Platelets. 2007;18(3):217-223. (Pubitemid 46744117)
93. Huang YQ, Li JJ, Karpatkin S. Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood. 2000;95(6):1993-1999. (Pubitemid 30151637)
94. Faghihi MA, Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 2009;10(9):637-643.
95. Carrieri C, Cimatti L, Biagioli M, et al. Long noncoding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454-457.
96. Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014;106(2):93-102.
97. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol. 1974;28(2):253-260.
98. Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738-740.
99. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet a-granules. Nat Genet. 2011;43(8):732-734.
100. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
101. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480(7376): 201-208.
102. Bunimov N, Fuller N, Hayward CPM. Genetic loci associated with platelet traits and platelet disorders. Semin Thromb Hemost. 2013;39(3):291-305.
103. Geisler T, Schaeffeler E, Gawaz M, Schwab M. Genetic variation of platelet function and pharmacology: an update of current knowledge. Thromb Haemost. 2013;110(5):876-887.
104. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010;116(15): 2627-2634.
105. Kunicki TJ, Williams SA, Nugent DJ. Genetic variants that affect platelet function. Curr Opin Hematol. 2012;19(5):371-379.
106. Park J-H, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570-575.
107. Brookfield JFY. Q&A: promise and pitfalls of genome-wide association studies. BMC Biol. 2010;8:41.
108. Kamatani Y, Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42(3): 210-215.
109. Lappalainen T, Sammeth M, Friedländer MR, et al; Geuvadis Consortium. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2013;501(7468): 506-511.